EGFR and non-small cell lung carcinoma: On the other hand, patients with NSCLC exhibiting both Neu5Gc-GM3 and EGFR positivity show significantly decreased OS compared to those with Neu5Gc-GM3-positive but EGFR-negative tumors (40.0% vs. 68.2%; p < 0.000) [50].